search
Back to results

The Effect of a Propionate Colon Release Form on ad Libitum Eating and Appetite Perception (METABIOTIC)

Primary Purpose

Overweight

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Ca-propionate 1 g
Ca-propionate 3 g
Placebo
Sponsored by
DSM Nutritional Products, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Overweight

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or non-pregnant, non-lactating females, 18-60 years of age
  2. Body mass index (BMI) ≥25 and <30 kg/m² at screening.
  3. Unrestrained eater (Score of ≤11 on the Eating Habits Questionnaire)
  4. Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial.
  5. Subject is willing to abstain from strenuous exercise, and consume alcoholic drinks 24 hours before study days and during study days.
  6. Willing to refrain from dietary supplement that are known to affect appetite (e.g. some herbal supplements), from prebiotic and probiotic supplements and large amounts of dietary fiber (inulin, metamucil, oat bran, etc) throughout the trial. On test days, subject agrees not to take any dietary supplements until dismissal from the GI labs. Failure to comply will result in a rescheduled test visit.
  7. Absence of health conditions that would prevent fulfillment of study requirements as judged by the Investigator on the basis of medical history.
  8. Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.
  9. Subject regularly has at least one bowel movement per day

Exclusion Criteria:

  1. Smokers
  2. Haemoglobin measurements of <120g/L for females and <130g/L for males (as per WHO criteria for anaemia).
  3. Fasting serum glucose (above or equal to 7.0mmol/L). AST, ALT, GGT and ALP >1.8 times upper limit of normal; creatinine >1.2 times upper limit of normal; fasting triglycerides >4.0 mmol/L; and electrolytes outside the normal range.
  4. Known history of AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary or GI disorders.
  5. Use of medications/dietary supplements known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or with any condition which might: 1) make participation dangerous to the subject or to others, or 2) affect the results as judged by the Investigator.
  6. History of propionic acidemia.
  7. Major trauma or surgical event within 3 months of screening.
  8. Unwillingness or inability to comply with the experimental procedures and to follow GI Labs safety guidelines.
  9. Known intolerance, sensitivity or allergy to any ingredients in the study products.
  10. Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc).
  11. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the average blood pressure measured at screening.
  12. Change in body weight of >3.5kg within 4 weeks of the screening visit.
  13. Presence of any signs or symptoms of an active infection within 5 d prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved and any treatment (i.e. antibiotic therapy) has been completed at least 4 weeks prior to each test visit.
  14. History of cancer in the prior two years, except for non-melanoma skin cancer.
  15. Recent history (within 12 months of screening) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as > 14 drinks per week (1 drink=12 oz beer, 5 oz wine, or 1.5 oz distilled spirits).
  16. Exposure to any non-registered drug product within 30 d prior to screening.
  17. Subject has donated more than 300 mL of blood during the three months prior to screening.
  18. Any history of an eating disorder (eg. anorexia nervosa, bulimia nervosa, binge eating) diagnosed by a health professional

Sites / Locations

  • GI Labs

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Propionate (1 g)

Propionate (3 g)

Placebo

Arm Description

Participants will receive 1 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.

Participants will receive 3 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.

Participants will receive 2.6 g of cellulose in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.

Outcomes

Primary Outcome Measures

Ad-libitum energy intake
Ad-libitum energy intake will be assessed by giving subjects a choice of an excess of individual pizza slices

Secondary Outcome Measures

Subjective ratings of appetite and GI comfort
Subjective measurements of motivation to eat and GI physical comfort will be assessed using validated questionnaires, i.e. Visual Analog Scales (VAS). Each of the questions on the VAS is a 100 mm line anchored at each end with opposing statements. Participants mark a vertical line on the line at a point that they felt reflect their feelings at the moment the test was taken. Scores will be assessed by measuring the distance between the intersection of the vertical line with the line and the left end of the line. VAS include a set of questions, such as feelings of fullness, feelings of hunger, prospective food consumption.
24 h food intake
Completion of a food diary
Serum glucose
Serum glucose analysis will be done using either the Vitros 350 Chemistry System or an YSI model 2300/2700 STAT analyser
Plasma insulin
Plasma insulin will be measured using an insulin ELISA Immunoassay kit
Plasma ghrelin
Immunoassay kits will be used to measure plasma ghrelin
Plasma total glucagon-like peptide-1 (GLP-1)
Immunoassay kits will be used for measure plasma total GLP-1
Plasma peptide YY (PYY)
Immunoassay kits will be used for measure plasma PYY
Plasma propionate
Plasma propionate will be measured using HPLC MS/MS

Full Information

First Posted
July 9, 2019
Last Updated
March 27, 2020
Sponsor
DSM Nutritional Products, Inc.
Collaborators
Glycemic Index Laboratories, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT04019951
Brief Title
The Effect of a Propionate Colon Release Form on ad Libitum Eating and Appetite Perception
Acronym
METABIOTIC
Official Title
The Effect of a Standardized Liquid Breakfast Containing a Propionate Colon Release Form on ad Libitum Eating and Appetite Perception in Healthy Overweight Humans: A Double-blinded, Randomized, Cross-over Study.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
October 1, 2019 (Actual)
Study Completion Date
February 1, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
DSM Nutritional Products, Inc.
Collaborators
Glycemic Index Laboratories, Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The present study aims to investigate the effect of a standardized liquid breakfast containing a food grade propionate colon release form on ad libitum eating and appetite perception in healthy overweight humans using a double-blinded, randomized, cross-over study design
Detailed Description
To determine, in healthy overweight subjects, the acute effect of a standardized liquid breakfast containing a propionate colon release form compared with placebo on appetite and GI comfort, food intake, serum glucose and insulin, plasma ghrelin, total GLP-1 and serum PYY concentrations, and plasma propionate concentrations

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Propionate (1 g)
Arm Type
Experimental
Arm Description
Participants will receive 1 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
Arm Title
Propionate (3 g)
Arm Type
Experimental
Arm Description
Participants will receive 3 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive 2.6 g of cellulose in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
Intervention Type
Dietary Supplement
Intervention Name(s)
Ca-propionate 1 g
Intervention Description
1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
Intervention Type
Dietary Supplement
Intervention Name(s)
Ca-propionate 3 g
Intervention Description
3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
Primary Outcome Measure Information:
Title
Ad-libitum energy intake
Description
Ad-libitum energy intake will be assessed by giving subjects a choice of an excess of individual pizza slices
Time Frame
t=210 minutes
Secondary Outcome Measure Information:
Title
Subjective ratings of appetite and GI comfort
Description
Subjective measurements of motivation to eat and GI physical comfort will be assessed using validated questionnaires, i.e. Visual Analog Scales (VAS). Each of the questions on the VAS is a 100 mm line anchored at each end with opposing statements. Participants mark a vertical line on the line at a point that they felt reflect their feelings at the moment the test was taken. Scores will be assessed by measuring the distance between the intersection of the vertical line with the line and the left end of the line. VAS include a set of questions, such as feelings of fullness, feelings of hunger, prospective food consumption.
Time Frame
Every 30 minutes during an interval of 6 hours
Title
24 h food intake
Description
Completion of a food diary
Time Frame
Food intake is recorded from the time of the start of the ad-libitum food test until 24 hours later
Title
Serum glucose
Description
Serum glucose analysis will be done using either the Vitros 350 Chemistry System or an YSI model 2300/2700 STAT analyser
Time Frame
Every 30 minutes during an interval of 6 hours
Title
Plasma insulin
Description
Plasma insulin will be measured using an insulin ELISA Immunoassay kit
Time Frame
Every 30 minutes during an interval of 6 hours
Title
Plasma ghrelin
Description
Immunoassay kits will be used to measure plasma ghrelin
Time Frame
Every 30 minutes during an interval of 6 hours
Title
Plasma total glucagon-like peptide-1 (GLP-1)
Description
Immunoassay kits will be used for measure plasma total GLP-1
Time Frame
Every 30 minutes during an interval of 6 hours
Title
Plasma peptide YY (PYY)
Description
Immunoassay kits will be used for measure plasma PYY
Time Frame
Every 30 minutes during an interval of 6 hours
Title
Plasma propionate
Description
Plasma propionate will be measured using HPLC MS/MS
Time Frame
Every 30 minutes during an interval of 6 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or non-pregnant, non-lactating females, 18-60 years of age Body mass index (BMI) ≥25 and <30 kg/m² at screening. Unrestrained eater (Score of ≤11 on the Eating Habits Questionnaire) Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial. Subject is willing to abstain from strenuous exercise, and consume alcoholic drinks 24 hours before study days and during study days. Willing to refrain from dietary supplement that are known to affect appetite (e.g. some herbal supplements), from prebiotic and probiotic supplements and large amounts of dietary fiber (inulin, metamucil, oat bran, etc) throughout the trial. On test days, subject agrees not to take any dietary supplements until dismissal from the GI labs. Failure to comply will result in a rescheduled test visit. Absence of health conditions that would prevent fulfillment of study requirements as judged by the Investigator on the basis of medical history. Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator. Subject regularly has at least one bowel movement per day Exclusion Criteria: Smokers Haemoglobin measurements of <120g/L for females and <130g/L for males (as per WHO criteria for anaemia). Fasting serum glucose (above or equal to 7.0mmol/L). AST, ALT, GGT and ALP >1.8 times upper limit of normal; creatinine >1.2 times upper limit of normal; fasting triglycerides >4.0 mmol/L; and electrolytes outside the normal range. Known history of AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary or GI disorders. Use of medications/dietary supplements known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or with any condition which might: 1) make participation dangerous to the subject or to others, or 2) affect the results as judged by the Investigator. History of propionic acidemia. Major trauma or surgical event within 3 months of screening. Unwillingness or inability to comply with the experimental procedures and to follow GI Labs safety guidelines. Known intolerance, sensitivity or allergy to any ingredients in the study products. Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc). Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the average blood pressure measured at screening. Change in body weight of >3.5kg within 4 weeks of the screening visit. Presence of any signs or symptoms of an active infection within 5 d prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved and any treatment (i.e. antibiotic therapy) has been completed at least 4 weeks prior to each test visit. History of cancer in the prior two years, except for non-melanoma skin cancer. Recent history (within 12 months of screening) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as > 14 drinks per week (1 drink=12 oz beer, 5 oz wine, or 1.5 oz distilled spirits). Exposure to any non-registered drug product within 30 d prior to screening. Subject has donated more than 300 mL of blood during the three months prior to screening. Any history of an eating disorder (eg. anorexia nervosa, bulimia nervosa, binge eating) diagnosed by a health professional
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Wolever
Organizational Affiliation
GI Labs
Official's Role
Principal Investigator
Facility Information:
Facility Name
GI Labs
City
Toronto
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effect of a Propionate Colon Release Form on ad Libitum Eating and Appetite Perception

We'll reach out to this number within 24 hrs